Maraviroc Intensification of cART in Patients with Suboptimal Immunological Recovery: A 48-Week, Placebo-Controlled Randomized Trial

van Lelyveld, SFL
Drylewicz, J
Krikke, M
Veel, EM
Otto, SA
Richter, C
Soetekouw, R
Prins, JM
Brinkman, K
Mulder, JW
Kroon, F
Middel, A
Symons, J
Wensing, AMJ
Nijhuis, M
Borghans, JAM
Tesselaar, K
Hoepelman, AIM

Open PDF

Open link

Publication date

July 2015

DOI

10.1371/journal.pone.0132430

Publisher

Public Library of Science (PLoS)

Journal

PLoS ONE

Abstract

OBJECTIVE: The immunomodulatory effects of the CCR5-antagonist maraviroc might be beneficial in patients with a suboptimal immunological response, but results of different cART (combination antiretroviral therapy) intensification studies are conflicting. Therefore, we performed a 48-week placebo-controlled trial to determine the effect of maraviroc intensification on CD4+ T-cell counts and immune activation in these patients. DESIGN: Double-blind, placebo-controlled, randomized trial. METHODS: Major inclusion criteria were 1. CD4+ T-cell count <350 cells/μL while at least two years on cART or CD4+ T-cell count <200 cells/μL while at least one year on cART, and 2. viral suppression for at least the previous 6 months. HIV-infected patients we...